<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO>WSJ920303-0034</DOCNO><DOCID>920303-0034.</DOCID><HL>   Technology Brief -- Repligen Corp.:   Concern Creates Partnership   To Test and Develop Drug</HL><DATE>03/03/92</DATE><SO>WALL STREET JOURNAL (J), PAGE C20</SO><CO>   RGEN</CO><MS>TECHNOLOGY (TEC)</MS><IN>ADVANCED TECHNOLOGY MEDICAL DEVICES (MDV)MEDICAL andamp; BIOTECHNOLOGY, GENETIC RESEARCH, PROSTHETICS (MTC)</IN><RE>MASSACHUSETTS (MA)NORTH AMERICA (NME)UNITED STATES (US)</RE><LP>   Repligen Corp., Cambridge, Mass., said it formed a $45million research and development partnership to test anddevelop an experimental drug, recombinant platelet factor-4,or rPF4, to treat certain cancers and cardiovasculardisorders.   The partnership, Repligen Clinical Partners L.P., will payRepligen to conduct clinical testing and further developmentof the genetically engineered drug, the biotechnology concernsaid. Repligen will have exclusive rights to market the drugin the U.S., Europe and Canada. The partnership will haverights to receive certain payments and part of the futuresales of the drug. Investors in the partnership also willreceive warrants to buy Repligen's common, the company said.</LP><TEXT>   Repligen said rPF4 has shown promise in preventing theformation of blood vessels that accompany and promote tumorgrowth. The company plans first to test the drug to treatacquired immune deficiency syndrome patients who haveKaposi's sarcoma, a kind of skin cancer, and brain tumorpatients.</TEXT></DOC>